Objective:To study the mechanism of levotinib regulating VEGFR/NF-κB/R1P2 signaling in primary hepatocellular carcinoma. Methods:Eighty patients with primary liver cancer admitted to our hospital from March 2016 to October 2017 were enrolled in the study. The patients were treated with oral levoftenib 24 mg daily until the disease progressed and intolerance was unacceptable. Drug efficacy and adverse reactions were evaluated in patients; immunohistochemistry was used to detect the expression of VEGFR2 protein in cancer tissues; Real-Time PCR and Western Blot were used to detect NF-κB, R1P2, BCL-2, BCL-xl and Caspase3 mRNA expression and phosphorylated protein levels. Results:The effective rate of Lefatinib in the treatment of primary hepatocellular carcinoma was 57.50%. Compared with paracancerous tissues, the expression of NF-κB, R1P, BCL-xl, Caspase3 mRNA and protein in primary hepatocellular carcinoma was significantly increased, and the contents of VEGFR2, BCL-2 mRNA and protein were significantly decreased after lovastinib was treated with Lefatinib. The difference was statistically significant (P<0.05). Conclusion:Levitinib regulates the expression of VEGFR/NF-κB/R1P2 in hepatocellular carcinoma and promotes the apoptosis of hepatoma cells. The incidence of adverse reactions of levabinib in the treatment of primary liver cancer is low, and the clinical application is safe. |
[1] 孔祥亘,韩绍磊,郑昭敏,等.高尔基体蛋白73联合甲胎蛋白异质体在原发性肝癌诊断中的价值[J].山东大学学报:医学版,2011,49(4):110-114.
[2] 王静,石明伟,张侠.甲胎蛋白阴性原发性肝癌诊断进展[J].医学综述,2016,22(2):269-273.
[3] 王志有.原发性肝癌血清AFU、AFP、CHE及γ-GT联合检测的分析[J].医学检验,2011,18(2):74-75.
[4] 甘雨,于新发,周成宇,等.甲胎蛋白在原发性肝癌的诊断和预后判断中的临床价值[J].海南医学,2016,27(6):891-894.
[5] 郭佳培,吴景华,李雷雷,等.AKT-GSK-3β信号途径在下调肝癌细胞化疗敏感性中的作用研究[J].标记免疫分析与临床,2016,23(3):316-318.
[6] 李雷雷,郭彬,郭佳培,等.M2型肿瘤相关巨噬细胞通过p53途径下调肝癌化疗敏感性的机制研究[J].标记免疫分析与临床,2017,24(3):308-313.
[7] 中国抗癌协会肝癌专业委员会,中华医学会编著.原发性肝癌诊断标准(中国抗癌协会肝癌专业委员会2001年修订)[J].临床诊疗指南:肿瘤分册,2005,11(1),322-323.
[8] SCHlUMBERGER M,TAHARA M,WIRTH L J,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med,2015,372(7):621-630.
[9] 王雪,徐文方,吴敬德.乐伐替尼合成路线图解[J].中国药物化学杂志,2016,26(2):157-159.
[10] 王凌霄,肖典,周辛波.口服多靶点酪氨酸激酶抑制剂-乐伐替尼[J].临床药物治疗杂志,2015,13(5):11-14.
[11] 许佳音,郑建洪.乐伐替尼的药理和临床评价[J].中国新药杂志,2016,25(7):725-727.
[12] LOCATI L D,LICITRA L,AGATE L,et al.Treatment of advanced thyroid cancer with axitinib:Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments[J].Cancer,2014,120(17):2694-2703.
[13] 刘伟,卞秀华,纪红.鼻咽癌患者血清VEGF和MMP-9水平的变化及其临床意义[J].现代医学,2016,44(12):1651-1654.
[14] 罗卫民,罗湘玉,郭家龙,等.miR-200b靶向VEGF抑制肺癌细胞侵袭[J].中南医学科学杂志,2016,44(3):271-274.
[15] 魏刚.VEGF、TrKB及Flt-4表达水平与老年鼻咽癌患者肿瘤侵袭、转移的相关性分析[J].现代医学,2016,44(7):969-971.
[16] 韩岚,梁杰,张艳艳,等.桃红四物汤对产后血瘀大鼠血清NO、子宫组织VEGF的表达及对PI3K/Akt信号通路的影响[J].中华中医药杂志,2016,31(5):1625-1629. |
